Threshold Reports Positive Phase II Results For Glufosfamide For Advanced Pancreatic Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Company is exploring next steps for the oncologic in the pancreatic cancer setting while trials are ongoing for other cancers.
You may also be interested in...
Threshold Halts Development Of Glufosfamide In Lung Cancer
Announcement comes after drug failed to produce more than one confirmed partial response in first stage of a Phase II trial.
Threshold Halts Development Of Glufosfamide In Lung Cancer
Announcement comes after drug failed to produce more than one confirmed partial response in first stage of a Phase II trial.
Threshold’s Glufosfamide Misses Endpoint In Phase III For Refractory Pancreatic Cancer
Final results from separate Phase II first-line pancreatic cancer trial with Lilly’s Gemzar due in third quarter; company had reported “encouraging” top-line data in December.